GE Healthcare has exercised its exclusive option to license PhotoCure's Hexvix optical molecular imaging agent for the U.S. market.
The U.S. license is an extension of an agreement inked earlier this year that granted the Chalfont St. Giles, U.K.-based firm exclusive global rights outside the Nordic region for Hexvix. The licensing deal is subject to U.S. government approval.
Hexvix is intended for the diagnosis and monitoring of bladder cancer. Oslo, Norway-based PhotoCure will continue to be responsible for manufacturing and Nordic distribution of the agent.
By AuntMinnie.com staff writers
July 31, 2006
Related Reading
GE signs Tulane, July 25, 2006
GE debuts wireless telemetry service, July 24, 2006
DirectPointe partners with GE, InterMountain, July 18, 2006
GE creates new ultrasound units, July 18, 2006
GE, PhotoCure ink optical imaging deal, January 9, 2006
Copyright © 2006 AuntMinnie.com
